Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders	Bronchiolitis Obliterans, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, connective tissue disorder, cryptogenic organizing pneumonia, glomerulonephritis, graft versus host disease, immune system disorder, kidney disorder, lung disorder, lupus nephritis, nephritis, obstructive lung disease, respiratory system disorder, skin disorder, systemic lupus erythematosus, systemic sclerosis, urinary system disorder	Recruiting	Phase 1 / Phase 2	2026-10-06		NCT06434363

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
MD Anderson Cancer Center	Houston	United States	589
The University of Texas Health Science Center at Houston	Houston	United States	207